Attendee search 

Tasly Biopharmaceuticals Co. Ltd. (Shanghai, China) is a subsidiary and the innovative R&D unit of Tasly Pharmaceutical Co. Ltd. The company develops, produce and promote biological therapeutical products across cardiavasular, metabolic and oncological area.

Global medical device company focused on oncology and interventional therapy.

Tasly Pharmaceutical was founded in 1994 and listed in Shanghai Stock Exchange in 2002, which is a pioneer and leading player in China's pharmaceutical industry focusing on developing, manufacturing and commercializing traditional Chinese medicine, biological drugs and chemical drugs. Tasly Biopharmaceuticals Co., Ltd. is a subsidiary of Tasly Pharmaceutical and a leading innovative biopharmaceutical company in China with integrated commercialization platform spanning the entire biologics value chain.
Tasly Biopharma with its headquarter in Shanghai focuses on the development of biologic drugs in the therapeutic areas of cardiovascular diseases, oncology and autoimmune, and alimentary tract and metabolism. Our target therapeutic areas are among the largest and fastest growing therapeutic areas in China, where biologics are expected to become one of the key growth drivers.
Pro-UK is an innovative biologics drug manufactured and commercialized by Tasly Biopharma, which is indicated for STEMI thrombolysis with a better efficacy and safety profile than alteplas. In addition to Pro-UK, we have a rich biopharmaceutical products under development.
Tasly has collaborated with various overseas companies, including Transgene, Pharnext, EA, Eli Lilly, APbio, etc.. Some of the assets from collaboration have been successfully transferred to China, and clinical trials have been initiated.
Tasly is actively looking for partnerships on clinical-stage to marketed assets, through straight licensing, co-development, strategic investment, etc. in the abovementioned disease areas to bring the asset to China market.

A start up company

A venture capital fund focused on healthcare industry.

we are a company focusing on the research and development of new drug

IHM-GBA is short for Innovation center of High-performance Medical device in Greater Bay Area. It's based in Guangzhou of Guangdong province in China. We focus on investment, partnership, and collaboration in global disruptive technology in medical device. We aim at helping global startups to enter into and develop the Chinese market. We are in comprehensive discussion with companies in terms of investment, partnership, licensing, and others.

专业投资医疗医药大健康项目

专注医疗投资

CRO based in Shanghai